Aurinia Pharmaceuticals Inc. (AUPH)
NASDAQ: AUPH · Real-Time Price · USD
15.33
-0.02 (-0.13%)
May 29, 2026, 4:00 PM EDT - Market closed
Aurinia Pharmaceuticals Employees
Aurinia Pharmaceuticals had 128 employees as of December 31, 2025. The number of employees decreased by 2 or -1.54% compared to the previous year.
Employees
128
Change (1Y)
-2
Growth (1Y)
-1.54%
Revenue / Employee
$2,330,430
Profits / Employee
$2,329,789
Market Cap
1.97B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 128 | -2 | -1.54% |
| Dec 31, 2024 | 130 | -170 | -56.67% |
| Dec 31, 2023 | 300 | 0 | - |
| Dec 31, 2022 | 300 | 0 | - |
| Dec 31, 2021 | 300 | 6 | 2.04% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Zai Lab | 1,784 |
| Ascentage Pharma Group International | 767 |
| ADMA Biologics | 647 |
| Viridian Therapeutics | 252 |
| Zymeworks | 243 |
| Stoke Therapeutics | 170 |
| Tyra Biosciences | 87 |
| Rapport Therapeutics | 84 |
AUPH News
- 22 days ago - Aurinia Pharmaceuticals reports Q1 EPS 25c, consensus 20c - TheFly
- 22 days ago - Aurinia Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2026 and Provides Update on Recent Business Progress - Business Wire
- 22 days ago - Aurinia Pharmaceuticals Earnings release: Q1 2026 - Filings
- 22 days ago - Aurinia Pharmaceuticals Quarterly report: Q1 2026 - Filings
- 5 weeks ago - Aurinia Pharmaceuticals Proxy statement: Proxy filing - Filings
- 2 months ago - Kezar Life Sciences takeover valuation ‘makes sense,’ says Jefferies - TheFly
- 2 months ago - Aurinia to acquire Kezar Life Sciences for $6.955 in cash per share plus CVR - TheFly
- 2 months ago - Aurinia Pharmaceuticals to Acquire Kezar Life Sciences for $6.955 in Cash per Share Plus a Contingent Value Right - Business Wire